Comparative performance of two drug interaction screening programmes analysing a cross-sectional prescription dataset of 84,625 psychiatric inpatients

Drug Safety

Volumn 36, Issue 4, 2013, Pages 247-258

  Zorina, Olesya I ^a   Haueis, Patrick ^a   Greil, Waldemar ^b   Grohmann, Renate ^b   Kullak Ublick, Gerd A ^a,c   Russmann, Stefan ^a,c  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTICOAGULANT AGENT; ATAZANAVIR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; CELECOXIB; CISAPRIDE; CLARITHROMYCIN; DICLOFENAC; DIGOXIN; ERYTHROMYCIN; FENOTEROL; FENTANYL; FLUVOXAMINE; GINKGO BILOBA EXTRACT; HALOPERIDOL; IBUPROFEN; LEVODOPA; LITHIUM; MEFENAMIC ACID; MIDAZOLAM; PANTOPRAZOLE; ROFECOXIB; SALMETEROL; THIORIDAZINE; TIAPRIDE; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ADOLESCENT; ADULT; AGED; ANALYZER; ARTICLE; BLEEDING; BRONCHOSPASM; CARBAMAZEPINE TOXICITY; CHILD; CLASSIFICATION; CLINICAL DECISION SUPPORT SOFTWARE; COMPARATIVE STUDY; DECISION SUPPORT SYSTEM; DEMOGRAPHY; DIGITALIS INTOXICATION; DRUG INTERACTION; DRUG INTOXICATION; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GASTROINTESTINAL HEMORRHAGE; GINKGO BILOBA; HEART ARRHYTHMIA; HUMAN; LITHIUM INTOXICATION; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; MOOD DISORDER; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; QT PROLONGATION; RETROSPECTIVE STUDY; SCHIZOPHRENIA; SCHOOL CHILD; SEIZURE; SEROTONIN SYNDROME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CROSS-SECTIONAL STUDIES; DECISION SUPPORT SYSTEMS, CLINICAL; DRUG INTERACTIONS; FEMALE; HOSPITALS, PSYCHIATRIC; HUMANS; INPATIENTS; MALE; MENTAL DISORDERS; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; YOUNG ADULT;

EID: 84876738684     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-013-0027-9     Document Type: Article

References (40)

1. Gurwitz J, Field T, Judge J, Rochon P, Harrold L, Cadoret C, et al. The incidence of adverse drug events in two large academic long-term care facilities. Am J Med. 2005;118(3):251-8.
2. Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients: excess length of stay, extra costs, and attributable mortality. JAMA. 1997;277(4):301-6.
3. Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc (Wash). 2001;41(2):192-9.
4. Bates DW, Cullen DJ, Laird N, Petersen LA, Small SD, Servi D, et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA. 1995;274(1):29-34.
5. Hansten PD. Drug interaction management. Pharm World Sci. 2003;25(3):94-7.
6. Kaushal R, Shojania KG, Bates DW. Effects of computerized physician order entry and clinical decision support systems on medication safety: a systematic review. Arch Intern Med. 2003;163(12):1409-16.
7. Garg AX, Adhikari NK, McDonald H, Rosas-Arellano MP, Devereaux PJ, Beyene J, et al. Effects of computerized clinical decision support systems on practitioner performance and patient outcomes: a systematic review. JAMA. 2005;293(10):1223-38.
8. Bergk V, Gasse C, Schnell R, Haefeli WE. Requirements for a successful implementation of drug interaction information systems in general practice: results of a questionnaire survey in Germany. Eur J Clin Pharmacol. 2004;60(8):595-602.
9. Indermitte J, Erba L, Beutler M, Bruppacher R, Haefeli WE, Hersberger KE. Management of potential drug interactions in community pharmacies: a questionnaire-based survey in Switzerland. Eur J Clin Pharmacol. 2007;63(3):297-305.
10. Hazlet TK, Lee TA, Hansten PD, Horn JR. Performance of community pharmacy drug interaction software. J Am Pharm Assoc (Wash). 2001;41(2):200-4.
11. Smith WD. Evaluation of drug interaction software to identify alerts for transplant medications. Ann Pharmacother. 2004;39(1):45-50.
12. Wang LM, Wong M, Lightwood JM, Cheng CM. Black box warning contraindicated comedications: concordance among three major drug interaction screening programs. Ann Pharmacother. 2010;44(1):28-34.
13. Fritz D, Ceschi A, Curkovic I, Huber M, Egbring M, Kullak-Ublick GA, et al. Comparative evaluation of three clinical decision support systems: prospective screening for medication errors in 100 medical inpatients. Eur J Clin Pharmacol. 2012;68(8):1209-19.
14. Glassman PA, Simon B, Belperio P, Lanto A. Improving recognition of drug interactions: benefits and barriers to using automated drug alerts. Med Care. 2002;40(12):1161-71.
15. Isaac T, Weissman JS, Davis RB, Massagli M, Cyrulik A, Sands DZ, et al. Overrides of medication alerts in ambulatory care. Arch Intern Med. 2009;169(3):305-11.
16. Bates DW. Ten commandments for effective clinical decision support: making the practice of evidence-based medicine a reality. J Am Med Inform Assoc. 2003;10(6):523-30.
17. van der Sijs H, Aarts J, Vulto A, Berg M. Overriding of drug safety alerts in computerized physician order entry. J Am Med Inform Assoc. 2006;13(2):138-47.
18. Fulda TR, Valuck RJ, Vander Zanden J, Parker S, Byrns PJ, The US Pharmacopeia Drug Utilization Review Advisory Panel. Disagreement among drug compendia on inclusion and ratings of drug-drug interactions. Curr Ther Res. 2000;61(8):540-8.
19. Hansten PD, Horn JR, Hazlet TK. ORCA: OpeRational ClassificAtion of drug interactions. J Am Pharm Assoc (Wash). 2001;41(2):161-5.
20. Vitry AI. Comparative assessment of four drug interaction compendia. Br J Clin Pharmacol. 2007;63(6):709-14.
21. Malone DC, Abarca J, Hansten PD, Grizzle AJ, Armstrong EP, Van Bergen RC, et al. Identification of serious drug-drug interactions: results of the partnership to prevent drug-drug interactions. J Am Pharm Assoc. 2004;44(2):142-51.
22. Frolich T, Zorina O, Fontana AO, Kullak-Ublick GA, Vollenweider A, Russmann S. Evaluation of medication safety in the discharge medication of 509 surgical inpatients using electronic prescription support software and an extended operational interaction classification. Eur J Clin Pharmacol. 2011;67(12):1273-82.
23. Guzek M, Zorina OI, Semmler A, Gonzenbach RR, Huber M, Kullak-Ublick GA, et al. Evaluation of drug interactions and dosing in 484 neurological inpatients using clinical decision support software and an extended operational interaction classification system (Zurich Interaction System). Pharmacoepidemiol Drug Saf. 2011;20(9):930-8.
24. Haueis P, Greil W, Huber M, Grohmann R, Kullak-Ublick GA, Russmann S. Evaluation of drug interactions in a large sample of psychiatric inpatients: a data interface for mass analysis with clinical decision support software. Clin Pharmacol Ther. 2011;90(4):588-96.
25. Zorina OI, Haueis P, Semmler A, Marti I, Gonzenbach RR, Guzek M, et al. Comparative evaluation of the drug interaction screening programs MediQ and ID PHARMA CHECK in neurological inpatients. Pharmacoepidemiol Drug Saf. 2012;21(8):872-80.
26. Rothschild JM, Mann K, Keohane CA, Williams DH, Foskett C, Rosen SL, et al. Medication safety in a psychiatric hospital. Gen Hosp Psychiatry. 2007;29(2):156-62.
27. Mojtabai R, Olfson M. National trends in psychotropic medication polypharmacy in office-based psychiatry. Arch Gen Psychiatry. 2010;67(1):26-36.
28. Weih M, Bachmeier C, Degirmenci U, Sojer R, Kreil S, Thurauf N, et al. Assessment of possible drug-drug interactions in psychopharmacotherapy after hospital discharge using an interactive database. Fortschr Neurol Psychiatr. 2011;79(2):92-6.
29. Grohmann R, Engel RR, Ruther E, Hippius H. The AMSP drug safety program: methods and global results. Pharmacopsychiatry. 2004;37(Suppl. 1):S4-11.
30. Engel RR, Grohmann R, Ruther E, Hippius H. Research methods in drug surveillance. Pharmacopsychiatry. 2004;37(Suppl. 1):S12-5.
31. Hansten PD, Horn JR. Drug interactions: analysis and management. St Louis: Wolters Kluwer Health: Facts & Comparisons, 2010.
32. Baxter K, Stockley IH. Stockley's drug interactions: a source book of interactions, their mechanisms, clinical importance, and management. 9th ed. London and Chicago: Pharmaceutical Press; 2010.
33. Woosley RL. Drugs that prolong the QT interval and/or induce torsades de pointes. Available from URL: http://www.azcert.org. Accessed 10 Aug 2012.
34. Jankel CA, Martin BC. Evaluation of six computerized drug interaction screening programs. Am J Hosp Pharm. 1992;49(6):1430-5.
35. Barrons R. Evaluation of personal digital assistant software for drug interactions. Am J Health Syst Pharm. 2004;61(4):380-5.
36. Abarca J, Colon LR, Wang VS, Malone DC, Murphy JE, Armstrong EP. Evaluation of the performance of drug-drug interaction screening software in community and hospital pharmacies. J Manag Care Pharm. 2006;12(5):383-9.
37. Vonbach P, Dubied A, Krähenbühl S, Beer JH. Evaluation of frequently used drug interaction screening programs. Pharm World Sci. 2008;30(4):367-74.
38. Abarca J, Malone DC, Armstrong EP, Grizzle AJ, Hansten PD, Van Bergen RC, et al. Concordance of severity ratings provided in four drug interaction compendia. J Am Pharm Assoc. 2004;44(2):136-41.
39. Vonbach P, Dubied A, Krahenbuhl S, Beer JH. Evaluation of frequently used drug interaction screening programs. Pharm World Sci. 2008;30(4):367-74.
40. Phansalkar S, Desai AA, Bell D, Yoshida E, Doole J, Czochanski M, et al. High-priority drug- drug interactions for use in electronic health records. J Am Med Inform Assoc. 2012;19(5):735-43.